ROSE-12
- Generic Name
- ROSE-12
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 219
- Registration Number
- NCT05907980
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸NEXT Oncology, Fairfax, Virginia, United States
🇯🇵National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath